regardless of positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from pharmacy benefit managers. These companies are typically erecting obstacles to reimbursement, like high cost criteria and appr